[Form 4] MYRIAD GENETICS INC Insider Trading Activity

Rhea-AI Filing Summary

Natalie Munk, Chief Accounting Officer of Myriad Genetics (MYGN), reported a disposition of common stock related to tax withholding on vested restricted stock units. The Form 4 shows a sale/disposition code (F) for 962 shares at a reported price of $7.77, leaving the reporting person with 45,167 shares held directly. The filing states the withheld shares were used to satisfy tax withholding obligations tied to the vesting of restricted stock units and that the number withheld was determined using Myriad's closing stock price on September 19, 2025. The Form 4 was signed on behalf of the reporting person.

Insights

Securities Analyst

TL;DR: Routine insider withholding to cover taxes on vested restricted stock units; not a strategic sale.

This transaction is recorded as a disposition under code F, which commonly denotes shares withheld by the company to satisfy tax obligations upon RSU vesting. The amount withheld (962 shares) is small relative to the remaining direct holding (45,167 shares). There is no indication in the filing of an open-market sale or a change in company role; disclosure is consistent with standard benefit vesting administration.

Corporate Governance Expert

TL;DR: Disclosure meets Section 16 requirements; action appears administrative rather than signaling a change in insider stance.

The narrative explanation explicitly states the shares were withheld to satisfy tax withholding tied to RSU vesting and that the withheld amount was based on the closing price on a specified date. The Form 4 identifies the reporting person as an officer and director, and the filing records direct ownership after withholding. This is a routine, administrative reporting event without additional governance implications disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Munk Natalie

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2025		F		962(1)	D	$7.77	45,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 19, 2025.

Remarks:

	By: Justin Hunter For: Natalie Munk	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Natalie Munk report on Form 4 for MYGN?

The filing reports a disposition of 962 shares of Myriad Genetics common stock under transaction code F related to tax withholding on vested RSUs.

How many shares does Natalie Munk own after the reported transaction (MYGN)?

The Form 4 shows 45,167 shares beneficially owned directly following the reported transaction.

At what price were the withheld shares reported for MYGN?

The withheld shares are reported at a price of $7.77 per share.

Why were the 962 shares disposed of according to the Form 4?

The filing explains the 962 shares were withheld by the company to satisfy tax withholding obligations arising from the vesting of restricted stock units.

Does the Form 4 indicate whether the transaction was an open-market sale for MYGN?

No. The filing indicates the shares were withheld by the company for tax withholding in connection with RSU vesting, not an open-market sale.